CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial

Inclusion Criteria: * First orthotopic heart transplant after 1st year * No rejection within previous 6 Months * Occurrence of squamous cell carcinoma, basal cell carcinoma, in situ carcinoma, Bowen disease, premalignant keratosis * Recurrence of skin cancers leading to immunosuppressive regimen modifications * Removal of a skin lesion in the past three years * Above 18 yrs and under contraceptive drugs if applicable * Informed consent given * Health coverage ongoing Exclusion Criteria: * Other non simultaneously transplanted organ * recent biopsy proven acute rejection * Proteinuria \> 1g/l * Ongoing infectious disease * HIV positivity, Chronic active Hepatitis B or C. * Abnormal blood tests: transaminases \>= 3UNL, Bilirubin \> 34 mmol.l, albumin\<35 g/l, spontaneous INR \>1,3 * Hemoglobin \>= 8 g/dl, White Blood Count\<= 2 giga/l, platelet count \<= 50 giga/l * Hypercholesterolemia\>= 9 mmol/l, hypertriglyceridemia \>= 8,5 mmol/l despite treatment * History of macrolid or mTor inhibitor intolerance * Previous cancer other than skin in the year prior to enrollment * Medical or surgical condition unsuitable for the trial * Breast feeding * Positive pregnancy test * Severe psychiatric disorder * Communication or language disability